ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 166,34
-0,90%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. HUTCHMED China Limited (HCM)

  7. HUTCHMED China Limited (HCM) Actualités

HCM HUTCHMED China Limited

18,675
-0,315 (-1,66%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
HUTCHMED China Limited HCM NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,315 -1,66% 18,675 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
18,99 17,46 18,99 18,16 18,99
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
26/4/202414:30GLOBEHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in..
05/4/202410:30GLOBEHUTCHMED Highlights Data to be Presented at..
02/4/202406:30GLOBEHUTCHMED and Innovent Jointly Announce NDA Acceptance in..
28/3/202401:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
22/3/202401:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
05/3/202412:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:40EDGAR2Form 20-F - Annual and transition report of foreign private..
28/2/202412:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
07/2/202412:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202401:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02/2/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202409:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202409:30GLOBEHUTCHMED to Announce 2023 Final Results
30/1/202412:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202405:53GLOBEHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval..
11/1/202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202408:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
11/1/202401:00GLOBEHUTCHMED Announces NDA Acceptance in China for Sovleplenib..
29/12/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202312:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202308:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
13/12/202305:30GLOBEHUTCHMED Announces Continued Inclusion of ELUNATE®..
13/12/202301:00GLOBEHUTCHMED Announces that it has Completed Enrollment of a..
07/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202308:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
01/12/202301:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at 2023..
30/11/202312:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/11/202314:35GLOBEDeutsche Bank ADR Investor Conference: Presentations Now..
09/11/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/11/202301:11GLOBEHUTCHMED Announces that Takeda Receives U.S. FDA Approval of..
01/11/202313:35GLOBEInternational companies to host live webcasts at Deutsche..
24/10/202312:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202310:30GLOBEHUTCHMED Highlights Clinical Data to be Presented at..
29/9/202312:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/9/202310:30GLOBEHUTCHMED Announces Submission of New Drug Application for..
14/9/202312:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202310:30GLOBEHUTCHMED Highlights Presentation of Results from the Phase..
12/9/202308:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
12/9/202302:00GLOBEHUTCHMED Completes Patient Enrollment of a Bridging Study of..
31/8/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202312:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202308:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
29/8/202302:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
21/8/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Dernières Valeurs Consultées

NASDAQ
HCM
HUTCHMED China
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés